New drug trial aims to ease heart failure in rare amyloid disease
NCT ID NCT07240844
First seen Nov 21, 2025 · Last updated May 25, 2026 · Updated 22 times
Summary
This study tests whether Enavogliflozin, a diabetes drug, can safely improve heart-related symptoms and daily function in 68 adults with amyloid cardiomyopathy. Participants will take the drug and a placebo in two separate periods to compare effects. The main goal is to see if the drug helps patients feel better and walk farther over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
Seoul, 06351, South Korea
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, 06591, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.